Esophageal Squamous Cell Carcinoma: all 657 studies
Page 4 of 7. Open to participants first (276), then studies with results posted, then the rest; newest registration first within each.
- Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction CancerCompletedNCT01178944Phase 2Results posted
- Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction CancerActive, not recruitingNCT01142388Phase 2Results posted
- Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based TherapyCompletedNCT01129206Phase 2Results posted
- Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell CarcinomaCompletedNCT00815308Phase 2Results posted
- Radiation Therapy, Pemetrexed Disodium, and Carboplatin in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By SurgeryTerminatedNCT00268437Phase 2Results posted
- A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction CancerTerminatedNCT00064259Phase 1/2Results posted
- Radiotherapy Target Volume in Locally Advanced Esophageal Squamous Cell Carcinoma in the Immunotherapy EraActive, not recruitingNCT07879898
- Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal DissectionActive, not recruitingNCT07757906Not applicable
- Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal CancerActive, not recruitingNCT07745322
- Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCCActive, not recruitingNCT07711470Phase 2
- Postoperative Radiotherapy and Lymph Node Dissection After Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell CarcinomaCompletedNCT07705412
- O-GlcNAcylation Induced HMGB1 SignallingActive, not recruitingNCT07702253
- Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaActive, not recruitingNCT07682376Phase 2
- an AI-Driven Four-Tier Invasion Depth Classification for Early Esophageal CancerActive, not recruitingNCT07605663
- A Single-center, Single-arm Clinical Study Evaluating the Short-term Efficacy of Inflatable Mediastinoscopic-assisted Transhiatal Laparoscopic Esophagectomy for the Radical Resection of Thoracic Esophageal CancerCompletedNCT07581236Not applicable
- Survival Prediction After Neoadjuvant Chemoimmunotherapy and Esophagectomy for Esophageal Squamous Cell CarcinomaCompletedNCT07488624
- Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell CarcinomaActive, not recruitingNCT07374003Phase 2
- Impact of Preserving Versus Ligating the Right Gastric Artery on Anastomotic Outcomes After McKeown Esophagectomy: A Randomized Controlled TrialCompletedNCT07363629Not applicable
- Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCCCompletedNCT07236320Not applicable
- A Retrospective Cohort Study of Patients Who Underwent Curative-intent Esophagectomy for ESCC at a Tertiary Referral Center in South KoreaCompletedNCT07201571
- Predicting Pathological Complete Response in Esophageal Squamous Cell Carcinoma Using a Multimodal Model Integrating Clinical, Radiomics, and Deep Learning FeaturesCompletedNCT07181850
- Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell CarcinomaActive, not recruitingNCT07147361
- A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT07142421Phase 2
- CT and Endoscopic Biopsy Image-Based Deep Learning for Predicting Left Recurrent Laryngeal Nerve Lymph Node Metastasis in Esophageal CancerActive, not recruitingNCT07074535
- Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell CarcinomaActive, not recruitingNCT06888531Phase 2
- Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell CarcinomaActive, not recruitingNCT06885814Phase 2
- The Neoadjuvant Treatment Modalities in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (NEO-EC）Active, not recruitingNCT06828718
- Safety and Tolerability of IPH4502 in Patients With Advanced Solid TumorsActive, not recruitingNCT06781983Phase 1
- Neoadjuvant Chemoradiotherapy Plus Surgery vs. Surgery Plus Adjuvant Therapy for ESCCCompletedNCT06775652Phase 3
- NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCCActive, not recruitingNCT06762158Not applicable
- Molecular Analysis of Gastric and OEsophageal Cancers STudyWithdrawnNCT06702384
- A Clinical Trial of Esophagectomy for Esophageal CarcinomaCompletedNCT06691503Phase 2
- Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell CarcinomasActive, not recruitingNCT06654297Phase 1
- A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 MutationTerminatedNCT06560645Phase 1
- Anastomotic Leaks in Esophageal Squamous Cell Carcinoma Patients After Trimodal TherapyCompletedNCT06556355
- A Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsCompletedNCT06549816Phase 1
- Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in FranceActive, not recruitingNCT06504615
- Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma（ChinECR）Active, not recruitingNCT06478355Not applicable
- a Neo-adjuvant Chemotherapy Immunotherapy in Resectable ESCC StudyActive, not recruitingNCT06472635
- Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)WithdrawnNCT06420908Not applicable
- Changhai Multimodal Esophageal Cancer CohortActive, not recruitingNCT06410677
- TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell CarcinomaActive, not recruitingNCT06401447Not applicable
- Exploring the Optimal Timing of Minimally Invasive Surgery for Esophageal Squamous Cell CarcinomaCompletedNCT06364566Not applicable
- PPIO-007 Correlation Analysis of Type II Diabetes Mellitus on Short-term and Long-term Outcomes of Patients With Esophageal Squamous Cell Cancer Undergoing Minimally Invasive EsophagectomyCompletedNCT06333665
- A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)Active, not recruitingNCT06304974Phase 3
- Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell CarcinomaCompletedNCT06281886Phase 2
- Machine Learning to Predict Lymph Node Metastasis in T1 Esophageal Squamous Cell CarcinomaCompletedNCT06256185Not applicable
- Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal CancerActive, not recruitingNCT06247956Phase 2
- Multi-institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell CarcinomaCompletedNCT06241079
- The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell CarcinomaCompletedNCT06241066
- PPIO-005 The Relationship Between Different Nutritional Pathways and Tumor Outcomes After Minimally Invasive EsophagectomyCompletedNCT06192212
- Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.CompletedNCT06190652
- HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell CarcinomaCompletedNCT06184841Phase 1
- Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell CarcinomaActive, not recruitingNCT06165380Phase 2
- Effect of Cervical Paraesophageal Lymph Node Metastasis Versus Supraclavicular Lymph Node Metastasis on the Overall Survival of Patients With Thoracic Esophageal Squamous Cell Carcinoma: An Observational StudyCompletedNCT06165094
- Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)Active, not recruitingNCT06143748Phase 2
- High-concentration Small-volume Versus Low-concentration Large-volume Iodine Solution for Esophageal ChromoendoscopyCompletedNCT06063941Not applicable
- Risk Factors of Relapse in Esophageal Squamous Cell Cancers Who Achieve PCR to Neoadjuvant ChemoradiotherapyActive, not recruitingNCT06061263
- Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer TypesTerminatedNCT06034860Phase 1
- A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT06022861Phase 3
- Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.Active, not recruitingNCT06020885Phase 1
- A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Phase 2
- Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCCActive, not recruitingNCT05951127Not applicable
- Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsActive, not recruitingNCT05945823Phase 2
- PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal CancerCompletedNCT05880082Phase 2
- Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid TumorsActive, not recruitingNCT05799274Phase 1
- Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell CarcinomaActive, not recruitingNCT05659251Phase 2
- Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）Status unknownNCT05650216Phase 2
- A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT05636150Phase 2
- Peripheral Blood Neoantigen Specific T Cells Predict the Efficacy of Immunotherapy for Esophageal Squamous Cell CarcinomaStatus unknownNCT05633641
- The Impact of Two-field or Three-field Lymphadenectomy on Overall Survival in Middle and Lower Thoracic Esophageal Squamous Cell Carcinoma: An Observational StudyCompletedNCT05617352
- Surgery Versus Non-surgical Treatment for Esophageal Squamous Cell Carcinoma in Patients Older Than 70 YearsCompletedNCT05604950
- Tislelizumab With Chemotherapy or Radiation for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma (TINES)Status unknownNCT05603065Phase 4
- RESECTED LYMPH NODES AND SURVIVAL OF PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA: AN OBSERVATIONAL STUDYStatus unknownNCT05570487
- Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell CancerStatus unknownNCT05561699Not applicable
- Identification of Breath Biomarkers in Esophageal CancerCompletedNCT05557955
- Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell CarcinomaStatus unknownNCT05552651Phase 2
- Efficacy and Safety of Tislelizumab and Nab-paclitaxel Combined With Low-dose Radiotherapy in Patients With Stage IVb Esophageal Squamous Cell CarcinomaStatus unknownNCT05547828Phase 2
- Pembrolizumab Plus CRT Followed by Surgery in Upper ESCCStatus unknownNCT05541445Phase 1/2
- AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCCStatus unknownNCT05522894Phase 2
- Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)Active, not recruitingNCT05520619Phase 2
- Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT05476380Phase 2
- Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCCStatus unknownNCT05469061Phase 2
- A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid TumorsTerminatedNCT05462873Phase 1
- Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 ResectionStatus unknownNCT05460403
- A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid TumorsTerminatedNCT05427396Phase 1
- ctDNA-based MRD Assessment in Local Advanced Esophageal CarcinomaStatus unknownNCT05426850
- Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of EsophagusStatus unknownNCT05424432Phase 2
- Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT05386056Phase 2
- Esophageal Arterial Infusion Chemotherapy Versus Systemic Intravenous Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Prospective, Multicentre, Randomised Controlled Clinical StudyStatus unknownNCT05381636Phase 2
- Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal CarcinomaCompletedNCT05355168Phase 2
- A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)CompletedNCT05342636Phase 1/2
- Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.Status unknownNCT05323890Phase 2
- A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCCStatus unknownNCT05317325Phase 1
- S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCCWithdrawnNCT05312372Phase 1/2
- Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaCompletedNCT05302011Phase 2
- Quantitative Analysis of 18F-FAPI Dynamic PET/CT for Accurate Differential Diagnosis of MLN of ESCCStatus unknownNCT05287880
- Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 BlockadeStatus unknownNCT05265962Phase 2
- Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCCStatus unknownNCT05213312Phase 2/3
- Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal FloraStatus unknownNCT05199649Not applicable